Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $10,778,636.00 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 492,400 shares of the business’s stock in a transaction that occurred on Tuesday, July 21st. The shares were sold at an average price of $21.89, for a total value of $10,778,636.00. Following the transaction, the insider owned 812,058 shares of the company’s stock, valued at $17,775,949.62. This represents a 37.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Stock Performance

Adaptive Biotechnologies stock opened at $24.18 on Friday. The company has a 50-day simple moving average of $19.25 and a 200-day simple moving average of $16.62. The firm has a market capitalization of $3.87 billion, a P/E ratio of -58.98 and a beta of 2.07. Adaptive Biotechnologies Corporation has a one year low of $9.96 and a one year high of $24.34.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Tuesday, July 28th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 33.98% and a negative net margin of 20.73%.The firm had revenue of $71.55 million during the quarter, compared to the consensus estimate of $65.44 million. During the same quarter last year, the company posted ($0.17) EPS. Adaptive Biotechnologies’s revenue for the quarter was up 21.5% on a year-over-year basis. As a group, sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Key Stories Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Adaptive outlined plans to separate its measurable residual disease (MRD) business and raised 2026 MRD revenue guidance to $268 million-$278 million. The higher outlook signals continued demand and may support a more focused valuation for the business. Adaptive outlines MRD separation plan while raising 2026 MRD revenue guidance
• Positive Sentiment: For the second quarter, ADPT reported a loss of approximately $0.10 per share, narrower than the $0.13 analyst consensus and substantially better than the $0.17 loss recorded a year earlier. Revenue of $71.55 million exceeded estimates of $65.44 million and grew 21.5% year over year. Adaptive Biotechnologies Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: TD Cowen raised its price target from $25 to $28 and maintained a Buy rating. BTIG Research also raised its target, from $24 to $25, while keeping a Buy rating. These revisions reinforce the improving analyst outlook following the results. Analyst price target updates
• Neutral Sentiment: Morgan Stanley increased its target from $20 to $22 but retained an Equal Weight rating, implying limited upside from recent trading levels. Brokerages overall maintain a “Moderate Buy” consensus, although the average target remains below the current market level. Morgan Stanley raises Adaptive Biotechnologies price target
• Negative Sentiment: Insider Harlan Robins sold 492,400 shares worth about $10.8 million under a pre-arranged Rule 10b5-1 plan. While scheduled selling reduces its signaling value, the transaction cut his direct holdings by 37.75% and could temper sentiment. Adaptive Biotechnologies insider share sale

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of institutional investors and hedge funds have recently modified their holdings of ADPT. Caitong International Asset Management Co. Ltd acquired a new position in shares of Adaptive Biotechnologies in the 4th quarter worth $28,000. EverSource Wealth Advisors LLC raised its position in shares of Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares during the period. Assetmark Inc. lifted its holdings in shares of Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after purchasing an additional 2,708 shares during the last quarter. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Adaptive Biotechnologies during the fourth quarter valued at $51,000. Finally, Strive Financial Group LLC acquired a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at $52,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analysts Set New Price Targets

ADPT has been the topic of several research analyst reports. BTIG Research lifted their price target on Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. Guggenheim lifted their target price on Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday. TD Cowen boosted their price target on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Morgan Stanley upped their price target on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and an average price target of $23.33.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.